Therapeutic effects of AE0047, a novel calcium antagonist, on progression of brain damage after stroke in stroke-prone spontaneously hypertensive rats.
1. The potential of AE0047, a novel calcium antagonist, to remedy brain damage of stroke-prone spontaneously hypertensive rats (SHRSPs) with signs of stroke was compared with those of nicardipine and hydralazine. 2. AE0047 (1 and 3 mg/kg/day) given daily to diseased SHRSPs prevented mortality and improved neurological symptoms. Histological examination also supported the effectiveness of AE0047 against the progression of the disease. 3. Nicardipine (10 mg/kg/day) and hydralazine (10 mg/kg/day) were less effective than AE0047 in a dose equal to or more than the hypotensive dose, respectively. 4. AE0047 may be beneficial for treating the acute stage of stroke in humans by virtue of its long-lasting hypotensive action and undefined direct actions on the cerebral vasculature.
Shinyama
H
H
Research Division, The Green Cross Corporation, Hirakata, Osaka, Japan. shinyama@greencross.co.jp
Nagai
H
H
Kawamura
T
T
Narita
Y
Y
Nakamura
N
N
Kagitani
Y
Y
D000818:Animals; D001921:Brain / Q000473:pathology; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D002561:Cerebrovascular Disorders / Q000188:drug therapy* / Q000473:pathology; D004095:Dihydropyridines / Q000627:therapeutic use*; D006830:Hydralazine / Q000627:therapeutic use; D008297:Male; D009529:Nicardipine / Q000627:therapeutic use; D051381:Rats; D011918:Rats, Inbred SHR; D014665:Vasodilator Agents / Q000627:therapeutic use
D002121:Calcium Channel Blockers; D004095:Dihydropyridines; D014665:Vasodilator Agents; C064970:AE0047; D006830:Hydralazine; D009529:Nicardipine